Hengrui Medicine Co., Ltd., commonly known as Hengrui Pharma, is a leading biopharmaceutical company headquartered in China (CN). Founded in 1993, Hengrui has established a strong presence in the global pharmaceutical industry, focusing on innovative drug development, manufacturing, and marketing. The company operates extensively across Asia, Europe, and North America, positioning itself as a key player in oncology, anaesthesia, and imaging agents.
Hengrui Pharma is renowned for its commitment to research and development, with a diverse portfolio that includes targeted therapies and biologics. Its unique approach to drug formulation and delivery has garnered recognition, contributing to its market leadership. With numerous accolades and a robust pipeline of products, Hengrui continues to advance healthcare solutions, making significant strides in improving patient outcomes worldwide.
-6 vs industry average
Hengrui Pharma’s score of 32 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Hengrui Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Hengrui Pharma's reported carbon emissions
In 2025, Hengrui Pharma reported total carbon emissions of approximately 1.08 billion kg CO2e, comprising 54,874,450 kg CO2e from Scope 1, 270,564,480 kg CO2e from Scope 2, and 756,662,330 kg CO2e from Scope 3 emissions. This marked a significant increase from the previous year's total emissions of approximately 257.9 million kg CO2e, which included 8,516,600 kg CO2e from Scope 1 and 249,380,640 kg CO2e from Scope 2. Hengrui Pharma has set ambitious climate commitments, aiming for carbon neutrality in its operations by 2025 for both Scope 1 and Scope 2 emissions. The company is exploring tailored pathways to achieve this goal. Additionally, it has outlined a long-term strategy to peak carbon emissions by 2029 and achieve full carbon neutrality by 2050, as part of a broader sustainable development roadmap. The emissions data is sourced from Jiangsu Hengrui Medicine Co., Ltd., and no cascaded data from a parent organization is reported. Hengrui Pharma's commitment to reducing its carbon footprint reflects its proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Hengrui Pharma’s Climate Goals (2030 & 2050)
5 goals2025
Our aim is to reduce carbon emissions during operations and…
Our aim is to reduce carbon emissions during operations and explore paths toward carbon neutrality tailored to our conditions.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 5 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Hengrui Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project